Details of the Drug

General Information of Drug (ID: DMPRI8G)

Drug Name
Buprenorphine
Synonyms
Buprel; Buprenex; Buprenophine; Buprenorfina; Buprenorphinum; Probuphine; Temgesic; Buprenorphine Hcl; RX 6029M; Buprenex (TN); Buprenorfina [INN-Spanish]; Buprenorphine [INN:BAN]; Buprenorphinum [INN-Latin]; Subutex (TN); Temgesic (TN); Buprenorphine (JAN/INN); RX-6029-M; Suboxone (TN); [5alpha,7alpha(S)]-17-(Cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-6,14-ethenomorphinan-7-methanol; (-)-buprenorphine; (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-(methyloxy)-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; (5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol; 17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 17-cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol; 2-(N-Cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-7alpha-yl)-3,3-dimethyl-2-butanol; 2-(N-cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol; 21-(Cyclopropyl-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 21-cyclopropyl-7alpha-(2-hydroxy-3,3-dimethyl-2-butyl)-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 21-cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine; 6,14-Ethenomorphinan-7-methanol; 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-, (alphaS,5alpha,7alpha)-(9CI); 6029-M
Indication
Disease Entry ICD 11 Status REF
Pain MG30-MG3Z Approved [1], [2]
Psychiatric disorder 6E8Z Phase 3 [3]
Migraine 8A80 Phase 2 [4]
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 467.6
Topological Polar Surface Area (xlogp) 5
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 7.651 mcgh/L [5]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 0.780 mcg/L [5]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1.5 h [5]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [6]
Clearance
The drug present in the plasma can be removed from the body at the rate of 19 mL/min/kg [7]
Elimination
It is primarily eliminated via feces (as free forms of buprenorphine and norbuprenorphine) while 10 - 30% of the dose is excreted in urine (as conjugated forms of buprenorphine and norbuprenorphine) [8]
Half-life
The concentration or amount of drug in body reduced by one-half in 30.75 hours (sublingually adminutesistered buprenorphine/naloxone 2mg/0.5mg) [5]
Metabolism
The drug is metabolized via the cytochrome P450 3A4/3A5-mediated N-dealkylation [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.03666 micromolar/kg/day [9]
Unbound Fraction
The unbound fraction of drug in plasma is 0.04% [7]
Vd
The volume of distribution (Vd) of drug is 188-335 L [8]
Water Solubility
The ability of drug to dissolve in water is measured as 17 mg/mL [6]
Chemical Identifiers
Formula
C29H41NO4
IUPAC Name
(1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol
Canonical SMILES
C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O
InChI
InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1
InChIKey
RMRJXGBAOAMLHD-IHFGGWKQSA-N
Cross-matching ID
PubChem CID
644073
ChEBI ID
CHEBI:3216
CAS Number
52485-79-7
DrugBank ID
DB00921
TTD ID
D06AWE
INTEDE ID
DR0246
ACDINA ID
D00082

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Opioid receptor mu (MOP) TTKWM86 OPRM_HUMAN Agonist [10], [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [12]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [13]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [14]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [15]
Cytochrome P450 3A5 (CYP3A5)
Main DME 		DEIBDNY CP3A5_HUMAN Substrate [16]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [17]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [14]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Substrate [18]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Pain
ICD Disease Classification MG30-MG3Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Opioid receptor mu (MOP) DTT OPRM1 5.94E-01 -0.02 -0.17
Cytochrome P450 2C18 (CYP2C18) DME CYP2C18 7.90E-01 3.72E-02 2.95E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 1.87E-01 4.98E-02 3.61E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 3.17E-01 -6.95E-02 -2.88E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 5.09E-02 -5.62E-02 -5.19E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 5.64E-01 2.36E-02 1.75E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 7.83E-01 2.32E-03 1.53E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 6.06E-01 -2.42E-02 -1.64E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Buprenorphine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Oxymorphone DM65AGJ Major Additive hypotensive effects by the combination of Buprenorphine and Oxymorphone. Pain [MG30-MG3Z] [88]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Buprenorphine and Dezocine. Pain [MG30-MG3Z] [88]
Flavoxate DMKV4NL Moderate Additive antimotility effects by the combination of Buprenorphine and Flavoxate. Pain [MG30-MG3Z] [89]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Buprenorphine and Hydrocodone. Pain [MG30-MG3Z] [88]
Ziconotide DMSLJP4 Major Additive CNS depression effects by the combination of Buprenorphine and Ziconotide. Pain [MG30-MG3Z] [90]
Coadministration of a Drug Treating the Disease Different from Buprenorphine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Buprenorphine and Ivosidenib. Acute myeloid leukaemia [2A60] [91]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Midostaurin. Acute myeloid leukaemia [2A60] [92]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Idarubicin. Acute myeloid leukaemia [2A60] [92]
Arn-509 DMT81LZ Moderate Increased metabolism of Buprenorphine caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [88]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Gilteritinib. Acute myeloid leukaemia [2A60] [93]
Oliceridine DM6MDCF Major Additive hypotensive effects by the combination of Buprenorphine and Oliceridine. Acute pain [MG31] [88]
Emapalumab DMZG5WL Moderate Altered metabolism of Buprenorphine due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [94]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Buprenorphine and Rivastigmine. Alzheimer disease [8A20] [92]
Siltuximab DMGEATB Moderate Altered metabolism of Buprenorphine due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [94]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Buprenorphine and Ivabradine. Angina pectoris [BA40] [94]
Nifedipine DMSVOZT Moderate Decreased metabolism of Buprenorphine caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [88]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Buprenorphine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [95]
Chlormezanone DMTWUXR Major Additive CNS depression effects by the combination of Buprenorphine and Chlormezanone. Anxiety disorder [6B00-6B0Z] [90]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Cilostazol. Arterial occlusive disease [BD40] [92]
Posaconazole DMUL5EW Moderate Decreased metabolism of Buprenorphine caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [88]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Buprenorphine and Levalbuterol. Asthma [CA23] [96]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Pirbuterol. Asthma [CA23] [97]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Buprenorphine and Salbutamol. Asthma [CA23] [96]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Buprenorphine and Formoterol. Asthma [CA23] [97]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [94]
Desipramine DMT2FDC Moderate Additive CNS depression effects by the combination of Buprenorphine and Desipramine. Attention deficit hyperactivity disorder [6A05] [98]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Ofloxacin. Bacterial infection [1A00-1C4Z] [99]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Buprenorphine caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [88]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Buprenorphine caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [88]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Buprenorphine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [92]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Buprenorphine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [99]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [99]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Norfloxacin. Bacterial infection [1A00-1C4Z] [99]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Levofloxacin. Bacterial infection [1A00-1C4Z] [99]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Buprenorphine caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [88]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [92]
Retigabine DMGNYIH Major Additive CNS depression effects by the combination of Buprenorphine and Retigabine. Behcet disease [4A62] [90]
Cariprazine DMJYDVK Major Additive CNS depression effects by the combination of Buprenorphine and Cariprazine. Bipolar disorder [6A60] [90]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Buprenorphine caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [88]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Eribulin. Breast cancer [2C60-2C6Y] [92]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Buprenorphine caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [88]
Tucatinib DMBESUA Moderate Decreased metabolism of Buprenorphine caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [88]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Bosutinib. Breast cancer [2C60-2C6Y] [94]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [100]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Buprenorphine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [97]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [96]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Buprenorphine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [97]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [97]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Buprenorphine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [97]
Dihydrocodeine DMB0FWL Major Additive hypotensive effects by the combination of Buprenorphine and Dihydrocodeine. Chronic pain [MG30] [88]
Levetiracetam DMTGDN8 Major Additive CNS depression effects by the combination of Buprenorphine and Levetiracetam. Chronic pain [MG30] [90]
Levomilnacipran DMV26S8 Moderate Additive CNS depression effects by the combination of Buprenorphine and Levomilnacipran. Chronic pain [MG30] [98]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Buprenorphine and Isoproterenol. Conduction disorder [BC63] [96]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Sevoflurane. Corneal disease [9A76-9A78] [92]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Probucol. Coronary atherosclerosis [BA80] [92]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Buprenorphine and Pasireotide. Cushing syndrome [5A70] [92]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Osilodrostat. Cushing syndrome [5A70] [94]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Buprenorphine caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [88]
MK-8228 DMOB58Q Moderate Decreased metabolism of Buprenorphine caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [88]
Sertraline DM0FB1J Moderate Additive CNS depression effects by the combination of Buprenorphine and Sertraline. Depression [6A70-6A7Z] [98]
Cyclobenzaprine DM1YBRM Major Additive CNS depression effects by the combination of Buprenorphine and Cyclobenzaprine. Depression [6A70-6A7Z] [90]
Vilazodone DM4LECQ Moderate Additive CNS depression effects by the combination of Buprenorphine and Vilazodone. Depression [6A70-6A7Z] [98]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Buprenorphine caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [88]
Vortioxetine DM6F1PU Moderate Additive CNS depression effects by the combination of Buprenorphine and Vortioxetine. Depression [6A70-6A7Z] [98]
Milnacipran DMBFE74 Moderate Additive CNS depression effects by the combination of Buprenorphine and Milnacipran. Depression [6A70-6A7Z] [98]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Buprenorphine and Escitalopram. Depression [6A70-6A7Z] [92]
Desvenlafaxine DMHD4PE Moderate Additive serotonergic effects by the combination of Buprenorphine and Desvenlafaxine. Depression [6A70-6A7Z] [98]
OPC-34712 DMHG57U Major Additive CNS depression effects by the combination of Buprenorphine and OPC-34712. Depression [6A70-6A7Z] [90]
Clomipramine DMINRKW Moderate Additive CNS depression effects by the combination of Buprenorphine and Clomipramine. Depression [6A70-6A7Z] [98]
Doxepin DMPI98T Moderate Additive CNS depression effects by the combination of Buprenorphine and Doxepin. Depression [6A70-6A7Z] [98]
Maprotiline DMPWB7T Moderate Additive CNS depression effects by the combination of Buprenorphine and Maprotiline. Depression [6A70-6A7Z] [98]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Buprenorphine and Esketamine. Depression [6A70-6A7Z] [101]
Mepenzolate DM8YU2F Moderate Additive antimotility effects by the combination of Buprenorphine and Mepenzolate. Digestive system disease [DE2Z] [89]
5-hydroxy-L-tryptophan DMDWZGJ Moderate Additive serotonergic effects by the combination of Buprenorphine and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [98]
Oxybutynine DMJPBAX Moderate Additive antimotility effects by the combination of Buprenorphine and Oxybutynine. Discovery agent [N.A.] [89]
Heroin diacetylmorphine DMDBWHY Major Additive CNS depression effects by the combination of Buprenorphine and Heroin diacetylmorphine. Dissociative neurological symptom disorder [6B60] [102]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [92]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Deutetrabenazine. Dystonic disorder [8A02] [103]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Buprenorphine and Ingrezza. Dystonic disorder [8A02] [104]
Felbamate DM1V5ZS Major Additive CNS depression effects by the combination of Buprenorphine and Felbamate. Epilepsy/seizure [8A61-8A6Z] [90]
Methsuximide DM6L5VO Major Additive CNS depression effects by the combination of Buprenorphine and Methsuximide. Epilepsy/seizure [8A61-8A6Z] [90]
Gabapentin DM6T924 Major Additive CNS depression effects by the combination of Buprenorphine and Gabapentin. Epilepsy/seizure [8A61-8A6Z] [90]
Cenobamate DMGOVHA Major Additive CNS depression effects by the combination of Buprenorphine and Cenobamate. Epilepsy/seizure [8A61-8A6Z] [90]
Phenacemide DMOHS9P Major Additive CNS depression effects by the combination of Buprenorphine and Phenacemide. Epilepsy/seizure [8A61-8A6Z] [90]
Fosphenytoin DMOX3LB Major Increased metabolism of Buprenorphine caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [105]
Brivaracetam DMSEPK8 Major Additive CNS depression effects by the combination of Buprenorphine and Brivaracetam. Epilepsy/seizure [8A61-8A6Z] [90]
Clonazepam DMTO13J Major Additive CNS depression effects by the combination of Buprenorphine and Clonazepam. Epilepsy/seizure [8A61-8A6Z] [90]
Rufinamide DMWE60C Major Additive CNS depression effects by the combination of Buprenorphine and Rufinamide. Epilepsy/seizure [8A61-8A6Z] [90]
Phenobarbital DMXZOCG Major Additive CNS depression effects by the combination of Buprenorphine and Phenobarbital. Epilepsy/seizure [8A61-8A6Z] [105]
Vigabatrin DMYT0OG Major Additive CNS depression effects by the combination of Buprenorphine and Vigabatrin. Epilepsy/seizure [8A61-8A6Z] [90]
Eslicarbazepine DMZREFQ Major Additive CNS depression effects by the combination of Buprenorphine and Eslicarbazepine. Epilepsy/seizure [8A61-8A6Z] [90]
Cannabidiol DM0659E Major Additive CNS depression effects by the combination of Buprenorphine and Cannabidiol. Epileptic encephalopathy [8A62] [90]
Dantrolene DM1D8XY Major Additive CNS depression effects by the combination of Buprenorphine and Dantrolene. Fever [MG26] [90]
Tazemetostat DMWP1BH Moderate Increased metabolism of Buprenorphine caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [106]
Solifenacin DMG592Q Moderate Additive antimotility effects by the combination of Buprenorphine and Solifenacin. Functional bladder disorder [GC50] [89]
Tolterodine DMSHPW8 Moderate Additive antimotility effects by the combination of Buprenorphine and Tolterodine. Functional bladder disorder [GC50] [89]
Itraconazole DMCR1MV Moderate Decreased metabolism of Buprenorphine caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [88]
Miconazole DMPMYE8 Moderate Decreased metabolism of Buprenorphine caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [88]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Buprenorphine caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [88]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [92]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Buprenorphine caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [88]
Telaprevir DMMRV29 Moderate Decreased metabolism of Buprenorphine caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [88]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Buprenorphine caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [88]
Rifapentine DMCHV4I Moderate Increased metabolism of Buprenorphine caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [88]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Buprenorphine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [88]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [107]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Buprenorphine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [88]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Buprenorphine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [108]
Etravirine DMGV8QU Moderate Increased metabolism of Buprenorphine caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [109]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [92]
Darunavir DMN3GCH Moderate Decreased metabolism of Buprenorphine caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [88]
Atazanavir DMSYRBX Moderate Decreased metabolism of Buprenorphine caused by Atazanavir mediated inhibition of UGT. Human immunodeficiency virus disease [1C60-1C62] [110]
BMS-201038 DMQTAGO Moderate Decreased metabolism of Buprenorphine caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [88]
Belladonna DM2RBWK Moderate Additive antimotility effects by the combination of Buprenorphine and Belladonna. Infectious gastroenteritis/colitis [1A40] [89]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Buprenorphine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [88]
Suvorexant DM0E6S3 Major Additive CNS depression effects by the combination of Buprenorphine and Suvorexant. Insomnia [7A00-7A0Z] [90]
Amobarbital DM0GQ8N Major Additive CNS depression effects by the combination of Buprenorphine and Amobarbital. Insomnia [7A00-7A0Z] [90]
Ramelteon DM7IW9J Major Additive CNS depression effects by the combination of Buprenorphine and Ramelteon. Insomnia [7A00-7A0Z] [90]
Zaleplon DMGFWSM Major Additive CNS depression effects by the combination of Buprenorphine and Zaleplon. Insomnia [7A00-7A0Z] [90]
Tasimelteon DMLOQ1V Major Additive CNS depression effects by the combination of Buprenorphine and Tasimelteon. Insomnia [7A00-7A0Z] [90]
Paraldehyde DMOC1BX Major Additive CNS depression effects by the combination of Buprenorphine and Paraldehyde. Insomnia [7A00-7A0Z] [90]
ITI-007 DMUQ1DO Major Additive CNS depression effects by the combination of Buprenorphine and ITI-007. Insomnia [7A00-7A0Z] [90]
Quazepam DMY4D87 Major Additive CNS depression effects by the combination of Buprenorphine and Quazepam. Insomnia [7A00-7A0Z] [90]
Estazolam DMZGXUM Major Additive CNS depression effects by the combination of Buprenorphine and Estazolam. Insomnia [7A00-7A0Z] [90]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Buprenorphine and Polyethylene glycol. Irritable bowel syndrome [DD91] [92]
Remimazolam DMLVSYX Major Additive CNS depression effects by the combination of Buprenorphine and Remimazolam. Labour/delivery anaesthesia complication [JB0C] [90]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Buprenorphine and Crizotinib. Lung cancer [2C25] [111]
PF-06463922 DMKM7EW Moderate Increased metabolism of Buprenorphine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [88]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Buprenorphine and Selpercatinib. Lung cancer [2C25] [94]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Buprenorphine and Lumefantrine. Malaria [1F40-1F45] [101]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Buprenorphine and Halofantrine. Malaria [1F40-1F45] [112]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Buprenorphine and Hydroxychloroquine. Malaria [1F40-1F45] [113]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Primaquine. Malaria [1F40-1F45] [92]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [94]
Idelalisib DM602WT Moderate Decreased metabolism of Buprenorphine caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [88]
IPI-145 DMWA24P Moderate Decreased metabolism of Buprenorphine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [88]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Buprenorphine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [114]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Buprenorphine and Vemurafenib. Melanoma [2C30] [92]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and LGX818. Melanoma [2C30] [92]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Buprenorphine caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [88]
Danazol DML8KTN Moderate Decreased metabolism of Buprenorphine caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [88]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Buprenorphine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [115]
Frovatriptan DM7RE8P Moderate Additive CNS depression effects by the combination of Buprenorphine and Frovatriptan. Migraine [8A80] [98]
Rizatriptan DMDJMA3 Moderate Additive CNS depression effects by the combination of Buprenorphine and Rizatriptan. Migraine [8A80] [98]
Naratriptan DMO50U2 Moderate Additive CNS depression effects by the combination of Buprenorphine and Naratriptan. Migraine [8A80] [98]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Buprenorphine and Lasmiditan. Migraine [8A80] [116]
Exjade DMHPRWG Moderate Increased metabolism of Buprenorphine caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [88]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Buprenorphine and Flibanserin. Mood disorder [6A60-6E23] [117]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Buprenorphine and Thalidomide. Multiple myeloma [2A83] [118]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Buprenorphine and Siponimod. Multiple sclerosis [8A40] [101]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Buprenorphine and Fingolimod. Multiple sclerosis [8A40] [92]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Buprenorphine and Ozanimod. Multiple sclerosis [8A40] [119]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Romidepsin. Mycosis fungoides [2B01] [92]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Buprenorphine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [88]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Dasatinib. Myeloproliferative neoplasm [2A20] [92]
Prasugrel DM7MT6E Moderate Altered absorption of Buprenorphine due to GI dynamics variation caused by Prasugrel. Myocardial infarction [BA41-BA43] [120]
Metoclopramide DMFA5MY Moderate Additive CNS depression effects by the combination of Buprenorphine and Metoclopramide. Nausea/vomiting [MD90] [121]
E-2007 DMJDYNQ Major Additive CNS depression effects by the combination of Buprenorphine and E-2007. Neuropathy [8C0Z] [90]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Buprenorphine and Bupropion. Nicotine use disorder [6C4A] [122]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Entrectinib. Non-small cell lung cancer [2C25] [92]
Sibutramine DMFJTDI Moderate Additive CNS depression effects by the combination of Buprenorphine and Sibutramine. Obesity [5B80-5B81] [98]
Dexfenfluramine DMJ7YDS Moderate Additive serotonergic effects by the combination of Buprenorphine and Dexfenfluramine. Obesity [5B80-5B81] [98]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Buprenorphine and Levomethadyl Acetate. Opioid use disorder [6C43] [94]
Lofexidine DM1WXA6 Moderate Additive hypotensive effects by the combination of Buprenorphine and Lofexidine. Opioid use disorder [6C43] [92]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Buprenorphine and Apraclonidine. Optic nerve disorder [9C40] [123]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Rucaparib. Ovarian cancer [2C73] [92]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Triclabendazole. Parasitic worm infestation [1F90] [92]
Pimavanserin DMR7IVC Major Additive CNS depression effects by the combination of Buprenorphine and Pimavanserin. Parkinsonism [8A00] [90]
Orphenadrine DMW542E Major Additive CNS depression effects by the combination of Buprenorphine and Orphenadrine. Parkinsonism [8A00] [90]
Abametapir DM2RX0I Moderate Decreased metabolism of Buprenorphine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [124]
Methylscopolamine DM5VWOB Moderate Additive antimotility effects by the combination of Buprenorphine and Methylscopolamine. Peptic ulcer [DA61] [89]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Famotidine. Peptic ulcer [DA61] [101]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Buprenorphine and Macimorelin. Pituitary gland disorder [5A60-5A61] [125]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Buprenorphine and Lefamulin. Pneumonia [CA40] [126]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Buprenorphine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [88]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Degarelix. Prostate cancer [2C82] [94]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and ABIRATERONE. Prostate cancer [2C82] [94]
Enzalutamide DMGL19D Moderate Increased metabolism of Buprenorphine caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [88]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Relugolix. Prostate cancer [2C82] [94]
Bicalutamide DMZMSPF Moderate Decreased metabolism of Buprenorphine caused by Bicalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [88]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Buprenorphine due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [94]
Ixekizumab DMXW92T Moderate Altered metabolism of Buprenorphine due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [94]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Buprenorphine and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [127]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Buprenorphine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [128]
Tocilizumab DM7J6OR Moderate Altered metabolism of Buprenorphine due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [94]
Canakinumab DM8HLO5 Moderate Altered metabolism of Buprenorphine due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [94]
Rilonacept DMGLUQS Moderate Altered metabolism of Buprenorphine due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [94]
Golimumab DMHZV7X Moderate Altered metabolism of Buprenorphine due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [94]
Dexamethasone DMMWZET Moderate Increased metabolism of Buprenorphine caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [88]
Sarilumab DMOGNXY Moderate Altered metabolism of Buprenorphine due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [94]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Quetiapine. Schizophrenia [6A20] [92]
Aripiprazole DM3NUMH Major Additive CNS depression effects by the combination of Buprenorphine and Aripiprazole. Schizophrenia [6A20] [90]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Buprenorphine and Iloperidone. Schizophrenia [6A20] [92]
Paliperidone DM7NPJS Major Additive CNS depression effects by the combination of Buprenorphine and Paliperidone. Schizophrenia [6A20] [90]
Molindone DMAH70G Major Additive CNS depression effects by the combination of Buprenorphine and Molindone. Schizophrenia [6A20] [90]
Thiothixene DMDINC4 Major Additive CNS depression effects by the combination of Buprenorphine and Thiothixene. Schizophrenia [6A20] [90]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Buprenorphine and Amisulpride. Schizophrenia [6A20] [129]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Asenapine. Schizophrenia [6A20] [92]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Buprenorphine and Pimozide. Schizophrenia [6A20] [94]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Buprenorphine caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [88]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Buprenorphine caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [94]
Larotrectinib DM26CQR Moderate Decreased metabolism of Buprenorphine caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [88]
Armodafinil DMGB035 Minor Increased metabolism of Buprenorphine caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [130]
LEE011 DMMX75K Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and LEE011. Solid tumour/cancer [2A00-2F9Z] [92]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Buprenorphine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [92]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [94]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [92]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Pitolisant. Somnolence [MG42] [94]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [92]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Buprenorphine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [131]
Brilinta DMBR01X Moderate Decreased metabolism of Buprenorphine caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [88]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Lenvatinib. Thyroid cancer [2D10] [92]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Buprenorphine and Cabozantinib. Thyroid cancer [2D10] [94]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Buprenorphine and Papaverine. Tonus and reflex abnormality [MB47] [132]
Elagolix DMB2C0E Moderate Increased metabolism of Buprenorphine caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [88]
Procainamide DMNMXR8 Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Procainamide. Ventricular tachyarrhythmia [BC71] [92]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Propafenone. Ventricular tachyarrhythmia [BC71] [92]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Buprenorphine and Flecainide. Ventricular tachyarrhythmia [BC71] [92]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Buprenorphine caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [92]
⏷ Show the Full List of 214 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Acesulfame E00341 36573 Flavoring agent
Hydrochloric acid E00015 313 Acidulant
Kyselina citronova E00014 311 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Maltitol E00423 493591 Binding agent; Coating agent; Diluent; Flavoring agent
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium citrate anhydrous E00102 6224 Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Sodium stearyl fumarate E00545 23665634 lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butylhydroxyanisole E00308 24667 Antimicrobial preservative; Antioxidant
Crospovidone E00626 Not Available Disintegrant
Dextrose anhydrous E00394 107526 Binding agent; Diluent; Flavoring agent; Tonicity agent
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium citrate dihydrate E00369 71474 Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water E00035 962 Solvent
Pregelatinized starch E00674 Not Available Binding agent; Diluent; Disintegrant
⏷ Show the Full List of 22 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Buprenorphine 2 mg tablet 2 mg Sublingual Tablet Oral
Buprenorphine 8 mg tablet 8 mg Sublingual Tablet Oral
Buprenorphine Hydrochloride eq 0.5mg base film eq 0.5mg base Film Buccal; Sublingual
Buprenorphine Hydrochloride eq 2mg base film eq 2mg base Film Buccal; Sublingual
Buprenorphine Hydrochloride eq 2mg base tablet eq 2mg base Tablet Sublingual
Buprenorphine Hydrochloride eq 0.3mg base/ml injectable eq 0.3mg base/ml Injectable Injection
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1670).
2 Buprenorphine for opioid dependence. J Pain Palliat Care Pharmacother. 2009;23(2):153-5.
3 ClinicalTrials.gov (NCT02510014) Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder.
4 ClinicalTrials.gov (NCT00941304) Study of BEMA Buprenorphine in the Treatment of Dental Pain. U.S. National Institutes of Health.
5 Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations. J Addict Med. 2019 Mar/Apr;13(2):93-103. doi: 10.1097/ADM.0000000000000457.
6 BDDCS applied to over 900 drugs
7 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
9 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10 Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8.
11 Partial versus full agonists for opioid-mediated analgesia--focus on fentanyl and buprenorphine. Acta Anaesthesiol Belg. 2002;53(3):193-201.
12 Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict. 2010 Jan-Feb;19(1):4-16.
13 Effect of nonspecific binding to microsomes and metabolic elimination of buprenorphine on the inhibition of cytochrome P4502D6. Biol Pharm Bull. 2005 Feb;28(2):212-6.
14 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
15 Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos. 2010 Jan;38(1):40-5.
16 Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med. 2019 Mar/Apr;13(2):93-103.
17 Buprenorphine in cancer pain. Support Care Cancer. 2005 Nov;13(11):878-87.
18 In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos. 2005 May;33(5):689-95.
19 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
20 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
21 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
22 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
23 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
24 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
25 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
26 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
27 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
28 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
29 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
30 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
31 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
32 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
33 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
34 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
35 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
36 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
37 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
38 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
39 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
40 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
41 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
42 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
43 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
44 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
45 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
46 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
47 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
48 Drug Interactions Flockhart Table
49 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
50 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
51 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
52 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
53 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
54 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
55 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
56 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
57 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
58 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
59 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
60 Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
61 Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys. 1997 Feb 15;338(2):157-64.
62 Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 Mar;9(2):365-73.
63 CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
64 Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242-51.
65 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
66 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
67 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
68 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
69 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
70 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
71 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
72 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
73 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
74 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
75 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
76 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
77 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
78 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
79 Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8.
80 Clinical pipeline report, company report or official report of signaturerx.
81 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
82 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
83 Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.
84 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
85 Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
86 Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
87 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
88 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
89 Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
90 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
91 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
92 Canadian Pharmacists Association.
93 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
94 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
95 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
96 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
97 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
98 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
99 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
100 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
101 Cerner Multum, Inc. "Australian Product Information.".
102 Schuman-Olivier Z, Hoeppner BB, Weiss RD, Borodovsky J, Shaffer HJ, Albanese MJ "Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes." Drug Alcohol Depend 132 (2013): 580-6. [PMID: 23688843]
103 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
104 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
105 Center for Substance Abuse Treatment.?Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2004. [PMID: 22514846]
106 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
107 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
108 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
109 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
110 Bruce RD, Altice FL "Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir." AIDS 20 (2006): 783-4. [PMID: 16514314]
111 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
112 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
113 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
114 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
115 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
116 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
117 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
118 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
119 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
120 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
121 Product Information. Reglan (metoclopramide). Wyeth-Ayerst Laboratories, Philadelphia, PA.
122 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
123 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
124 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
125 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
126 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
127 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
128 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
129 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
130 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
131 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
132 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]